A population-based recurrence risk management study of patients with pT1 node-negative HER2+?breast cancer: a National Clinical Database study.

ABSTRACT:

Purpose

Recurrence risk management of patients with small (??2 cm), node-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancer remains challenging. We studied the effects of adjuvant chemotherapy and/or trastuzumab and survival outcomes among these patients, using data from the population-based Japanese National Clinical Database (NCD).

Methods

We identified a cohort of 2736 breast cancer patients with HER2+?pT1N0 disease: 489 pT1a, 642 pT1b, and 1623 pT1c. The median observation period was 76 months, and the 5-year follow-up rate was 48.2%. The number of events was 212 for disease-free survival (DFS), 40 for breast cancer-specific survival, and 84 for overall survival (OS).

Results

There were 24.5% of pT1a, 51.9% of pT1b, and 63.3% of pT1c patients who were treated systemically after surgery. OS in pT1b (logrank test; p?=?0.03) and DFS in pT1c (logrank test; p?ConclusionsNCD data revealed that systemic treatment improved OS in pT1bc but not in pT1a node-negative HER2+?breast cancer patients. Future observational research using big-sized data is expected to play an important role in optimizing treatment for patients with early-stage breast cancer.

SUBMITTER: Kubo M 

PROVIDER: S-EPMC6817748 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature